Multiple Patent Expirations are Coming Up, Bringing in Large Number of Generic inhalers and nasal spray drugs, Says TMR The growing number of generic drugs in the market today is primarily attributed to the patent expirations in various medical fields, including inhalers and nasal sprays. The absence of the need for research and development or major marketing strategies allows the average price of generic drugs to have been US$35.22 in 2008, as opposed to the US$137.9 average for branded drugs, according to the NACDS. The sales of generic inhalers and nasal sprays is expected to increase even further after the release of studies that point to an increase in the number of patients suffering from restrictive and even life-threatening respiratory diseases, such as COPD and asthma. The incredibly high healthcare costs, especially in developed economies, is therefore driving this growing patient pool towards generic drugs. Quality control could pose an issue in the overall growth of generic inhalers and nasal spray sales, an issue that governments are trying to control through increasing the stringency of related regulatory frameworks and quality assurance measures.
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.